Symptomatic vitreomacular adhesion

Retina

Volumn 33, Issue 8, 2013, Pages 1503-1511

  Jackson, Timothy L ^a,b   Nicod, Elena ^c   Simpson, Andrew ^a,b   Angelis, Aris ^c   Grimaccia, Federico ^c   Kanavos, Panos ^c  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

age related macular degeneration; diabetic macular edema; macular hole; posterior vitreous detachment; retinal vein occlusion; vitreomacular traction; vitreomacularadhesion

Indexed keywords

OCRIPLASMIN;

CILIARY DISK; DIABETIC MACULAR EDEMA; EPIRETINAL MEMBRANE; INFORMATION RETRIEVAL; OPTICAL COHERENCE TOMOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA HOLE; RETINA MACULOPATHY; REVIEW; SYMPTOMATIC VITREOMACULAR ADHESION; VISION; VITRECTOMY; VITREOUS BODY DETACHMENT;

BLINDNESS; EYE DISEASES; HUMANS; MACULA LUTEA; RETINAL DISEASES; TISSUE ADHESIONS; VITREOUS BODY;

EID: 84883740775     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31829232fd     Document Type: Review

References (49)

1. Jackson TL, Nicod E, Angelis A, et al. Vitreous attachment in AMD, DME, and RVO: a systematic review and meta-analysis. Retina http://www.ncbi.nlm.nih. gov/pubmed/23591535
2. Gandorfer A, Rohleder M, Sethi C, et al. Posterior vitreous detachment induced by microplasmin. Invest Ophthalmol Vis Sci 2004;45:641-647.
3. Stalmans P, Delaey C, de Smet MD, et al. Intravitreal injection of microplasmin for treatment of vitreomacular adhesion: results of a prospective, randomized, sham-controlled phase II trial (the MIVI-IIT trial). Retina 2010;30:1122-1127.
4. Benz MS, Packo KH, Gonzalez V, et al. A placebo-controlled trial of microplasmin intravitreous injection to facilitate posterior vitreous detachment before vitrectomy. Ophthalmology 2010; 117:791-797.
5. de Smet MD, Gandorfer A, Stalmans P, et al. Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: theMIVI I trial. Ophthalmology 2009; 116:1349-1355, 1355.e1-2.
6. Sebag J. The vitreous. In: Hart EWM Jr, ed. Addler's Physiology of the Eye. 9th ed. London: Mosby; 1992:271-280.
7. Nordmann J. Biologie du corps vitré. In: Brini A, Bronner A, Gerhard JP, Nordmann J., eds. Biologie et chirurgie du corps vitré. Paris, France: Masson; 1968.
8. Foos RY, Wheeler NC. Vitreoretinal juncture. Synchysis senilis and posterior vitreous detachment. Ophthalmology 1982;89: 1502-1512.
9. Johnson MW. Posterior vitreous detachment: evolution and complications of its early stages. Am J Ophthalmol 2010;149:371-382.
10. Simpson A, Petrarca R, Jackson TL. Vitreomacular adhesion and neovascular age-related macular degeneration-a review. Surv Opthalmol http://www.ncbi.nlm. nih.gov/pubmed/23068973
11. Jackson TL, Marshall J. Fluorophore-assisted retinal break detection using antibodies to glial fibrillary acidic protein. Invest Ophthalmol Vis Sci 2004;45:993-1001.
12. Tanner V, Chauhan DS, Jackson TL, Williamson TH. Optical coherence tomography of the vitreoretinal interface in macular hole formation. Br J Ophthalmol 2001;85:1092-1097.
13. Gaudric A, Haouchine B, Massin P, et al. Macular hole formation: new data provided by optical coherence tomography. Arch Ophthalmol 1999;117:744-751.
14. Chauhan DS, Antcliff RJ, Rai PA, et al. Papillofoveal traction in macular hole formation: the role of optical coherence tomography. Arch Ophthalmol 2000;118:32-38.
15. Yanoff M, Fine B. Neurol (sensory) retina, Chapter 11. In: Vajpayee RB, ed. Ocular Pathology. 4th ed. London: Mosby; 1996:419-421.
16. Hikichi T, Yoshida A, Akiba J, Trempe CL. Natural outcomes of stage 1, 2, 3, and 4 idiopathic macular holes. Br J Ophthalmol 1995;79:517-520.
17. Sonmez K, Capone A Jr, Trese MT, Williams GA. Vitreomacular traction syndrome: impact of anatomical configuration on anatomical and visual outcomes. Retina 2008;28:1207-1214.
18. Melberg NS, Williams DF, Balles MW, et al. Vitrectomy for vitreomacular traction syndrome with macular detachment. Retina 1995;15:192-197.
19. Ezra E. Idiopathic full thickness macular hole: natural history and pathogenesis. Br J Ophthalmol 2001;85:102-108.
20. Jaycock PD, Bunce C, Xing W, et al. Outcomes of macular hole surgery: implications for surgical management and clinical governance. Eye (Lond) 2005;19:879-884.
21. Oono Y, Nakamura S, Yoshimura K, et al. Recurrence after spontaneous resolution of an idiopathic epiretinal membrane. Case Rep Ophthalmol 2011;2:55-58.
22. Meyer CH, Rodrigues EB, Mennel S, et al. Spontaneous separation of epiretinal membrane in young subjects: personal observations and review of the literature. Graefes Arch Clin Exp Ophthalmol 2004;242:977-985.
23. Garay-Aramburu G, Larrauri-Arana A. Spontaneous resolution of an idiopathic epiretinal membrane in a young patient [in Spanish]. Arch Soc Esp Oftalmol 2005;80:741-743.
24. Simpson A, Jackson A. An optical coherence tomography study of vitreomacular adhesion in neovascular age-related macular degeneration. Retina Submitted in 2012.
25. Yamakiri K, Sakamoto T, Noda Y, et al. One-year results of a multicenter controlled clinical trial of triamcinolone in pars plana vitrectomy. Graefes Arch Clin Exp Ophthalmol 2008; 246:959-966.
26. Sakamoto T, Miyazaki M, Hisatomi T, et al. Triamcinoloneassisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown. Graefes Arch Clin Exp Ophthalmol 2002;240:423-429.
27. Peyman GA, Cheema R, Conway MD, Fang T. Triamcinolone acetonide as an aid to visualization of the vitreous and the posterior hyaloid during pars plana vitrectomy. Retina 2000; 20:554-555.
28. Abdelkader E, Lois N. Internal limiting membrane peeling in vitreo-retinal surgery. Surv Ophthalmol 2008;53:368-396.
29. Rodrigues EB, Costa EF, Penha FM, et al. The use of vital dyes in ocular surgery. Surv Ophthalmol 2009;54:576-617.
30. Jackson TL. Indocyanine green accused. Br J Ophthalmol 2005;89:395-396.
31. Chang-Lin JE, Burke JA, Peng Q, et al. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci 2011;52:4605-4609.
32. Sakamoto T, Sheu SJ, Arimura N, et al. Vitrectomy for exudative age-related macular degeneration with vitreous hemorrhage. Retina 2010;30:856-864.
33. Roller AB, Mahajan VB, Boldt HC, et al. Effects of vitrectomy on age-related macular degeneration. Ophthalmology 2010; 117:1381-1386.
34. Chan CK, Wessels IF, Friedrichsen EJ. Treatment of idiopathic macular holes by induced posterior vitreous detachment. Ophthalmology 1995;102:757-767.
35. Mori K, Saito S, Gehlbach PL, Yoneya S. Treatment of stage 2 macular hole by intravitreous injection of expansile gas and induction of posterior vitreous detachment. Ophthalmology 2007;114:127-133.
36. Jorge R, Costa RA, Cardillo JA, et al. Optical coherence tomography evaluation of idiopathic macular hole treatment by gas-assisted posterior vitreous detachment. Am J Ophthalmol 2006;142:869-871.
37. Ochoa-Contreras D, Delsol-Coronado L, Buitrago ME, et al. Induced posterior vitreous detachment by intravitreal sulfur hexafluoride (SF6) injection in patients with nonproliferative diabetic retinopathy. Acta Ophthalmol Scand 2000;78:687-688.
38. McHugh D, Gupta B, Saeed M. Intravitreal gas injection for the treatment of diabetic macular edema. Clin Ophthalmol 2011;5:1543-1548.
39. Rodrigues IA, Stangos AN, McHugh DA, Jackson TL. Intravitreal injection of expansile perfluoropropane (C3F8) for the treatment of vitreomacular traction. Am J Ophthalmol http://www. ncbi.nlm.nih.gov/pubmed/23164159
40. Liotta LA, Goldfarb RH, Brundage R, et al. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 1981;41:4629-4636.
41. Russell SR, Shepherd JD, Hageman GS. Distribution of glycoconjugates in the human retinal internal limiting membrane. Invest Ophthalmol Vis Sci 1991;32:1986-1995.
42. Schneider EW, Johnson MW. Emerging nonsurgical methods for the treatment of vitreomacular adhesion: a review. Clin Ophthalmol 2011;5:1151-1165.
43. Margherio AR, Margherio RR, Hartzer M, et al. Plasmin enzyme-assisted vitrectomy in traumatic pediatric macular holes. Ophthalmology 1998;105:1617-1620.
44. Sakuma T, Tanaka M, Inoue J, et al. Use of autologous plasmin during vitrectomy for diabetic maculopathy. Eur J Ophthalmol 2006;16:138-140.
45. Williams JG, Trese MT,Williams GA, Hartzer MK. Autologous plasmin enzyme in the surgical management of diabetic retinopathy. Ophthalmology 2001;108:1902-1905; discussion 5-6.
46. Stalmans P, Benz MS, Gandorfer A, et al. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. New Engl J Med 2012;367:606-615.
47. Hirokawa H, Jalkh AE, Takahashi M, et al. Role of the vitreous in idiopathic preretinal macular fibrosis. Am J Ophthalmol 1986;101:166-169.
48. Appiah AP, Hirose T, Kado M. A review of 324 cases of idiopathic premacular gliosis. Am J Ophthalmol 1988;106:533-535.
49. Simpson ARH, Jackson TL. Chapter 2. The epidemiology of vitreo-macular interface diseases. In Diseases of the Vitreo-Macular Interface. Ed. Girach A, de Smet MD. Springer-Verlag 2012.